About Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. Its therapeutic offerings consist of products in the areas, such as Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. It offers products made from HA based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Its orthobiologics products primarily consist of viscosupplementation and regenerative orthopedics products. Its viscosupplementation franchise includes ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Health Care Supplies
- Exchange: NASDAQ
- Symbol: ANIK
- CUSIP: 03525510
- Previous Close: $49.09
- 50 Day Moving Average: $50.33
- 200 Day Moving Average: $47.76
- 52-Week Range: $41.38 - $54.96
- Trailing P/E Ratio: 23.03
- Foreward P/E Ratio: 25.68
- P/E Growth: 2.44
- Market Cap: $724.13M
- Outstanding Shares: 14,626,000
- Beta: 1.85
- Net Margins: 33.64%
- Return on Equity: 17.21%
- Return on Assets: 15.71%
Companies Related to Anika Therapeutics:
- Current Ratio: 21.25%
- Quick Ratio: 18.87%
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
Where is Anika Therapeutics' stock going? Where will Anika Therapeutics' stock price be in 2017?
2 brokers have issued 1-year price targets for Anika Therapeutics' shares. Their forecasts range from $49.00 to $50.00. On average, they expect Anika Therapeutics' share price to reach $49.50 in the next year.
When will Anika Therapeutics announce their earnings?
Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.
Who owns Anika Therapeutics stock?
Anika Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (5.00%), Thompson Siegel & Walmsley LLC (3.41%), State Street Corp (2.17%), Renaissance Technologies LLC (1.14%), AQR Capital Management LLC (0.78%) and Russell Investments Group Ltd. (0.77%). Company insiders that own Anika Therapeutics stock include Joseph I Bower and Raymond J Land.
Who sold Anika Therapeutics stock? Who is selling Anika Therapeutics stock?
Anika Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Renaissance Technologies LLC, AQR Capital Management LLC, Oxford Asset Management, Federated Investors Inc. PA, Cadence Capital Management LLC, O Shaughnessy Asset Management LLC and New York State Teachers Retirement System. Company insiders that have sold Anika Therapeutics stock in the last year include Joseph I Bower and Raymond J Land.
Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?
Anika Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., FMR LLC, Two Sigma Investments LP, State Street Corp, A.R.T. Advisors LLC, Tudor Investment Corp Et Al, Allianz Asset Management AG and Ladenburg Thalmann Financial Services Inc..
How do I buy Anika Therapeutics stock?
Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Anika Therapeutics stock cost?
One share of Anika Therapeutics stock can currently be purchased for approximately $49.57.